# National Emerging Infectious Diseases Laboratories Operations

> **NIH NIH UC7** · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $11,500,000

## Abstract

Overall
Abstract
The National Biocontainment Laboratory (NBL) at Boston University (BU) is known as the National Emerging
Infectious Diseases Laboratories (NEIDL). It is owned and operated by BU and is located on the Boston
University Medical Campus (BUMC) adjacent to the BU School of Medicine, the Graduate Sciences program,
the BU School of Public Health, and the affiliated teaching hospital, Boston Medical Center. The NEIDL's
missions are: (1) To perform innovative basic, translational and clinical research on emerging infectious
diseases in order to develop diagnostic tests, treatments and vaccines to promote the public's health; (2) To
provide training in these areas of research and to support a national response in the event of a biodefense
emergency; and (3) To establish a research facility with the highest attention to community and laboratory
safety and security. In order to successfully achieve these missions, the NEIDL's goals are to: (1) Recruit and
develop a cadre of investigators and research staff with expertise in the scientific disciplines required to
investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents, including
collaborations within the university, in the United States, and internationally; (2) Develop animal models for the
comparative study of these pathogens, mimicking as closely as possible the human disease process, and build
capacity for the creation and use of relevant animal models and innovative veterinary research support; (3)
Perform translational, preclinical and clinical research in animals and humans; (4) Develop the methodologies
needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents; (5)
Train the next generation of research scientists and related support personnel in the requirements to perform
maximum containment research in a safe and secure environment;( 6) Maintain the flexibility needed to
support a national response in the event of a biodefense emergency; (7) Establish a "safety first" environment
for the conduct of all activities in the Institute. Since opening for research at the BSL-4 and ABSL-4 levels in
2018, NEIDL has rapidly moved forward to recruit additional faculty whose skills and interests both expand and
complement existing expertise, bring innovative new insights and methodology to expand our scientific
capabilities, open up research on new pathogens. In order to advance vaccines and therapeutics, the NEIDL
has expanded its Regulatory Compliance Group and practices to permit studies to be carried out under Well-
Documented practices. The NEIDL focuses on and supports innovative science, led by our faculty
investigators, and as a result we also continue to evolve our integrated research support services to provide
support needed for BSL-4 research to better reflect and provide access to new technology and research
approaches, in order to remain at the leading edge of science.

## Key facts

- **NIH application ID:** 10892807
- **Project number:** 5UC7AI095321-11
- **Recipient organization:** BOSTON UNIVERSITY MEDICAL CAMPUS
- **Principal Investigator:** Nancy Jean Sullivan
- **Activity code:** UC7 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $11,500,000
- **Award type:** 5
- **Project period:** 2014-06-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10892807

## Citation

> US National Institutes of Health, RePORTER application 10892807, National Emerging Infectious Diseases Laboratories Operations (5UC7AI095321-11). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10892807. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*